The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911
Abstract
Advanced follicular lymphoma is incurable with conventional chemotherapy and radiotherapy. The Southwest Oncology Group (SWOG) conducted a phase 2 trial (S9911) of a novel regimen consisting of 6 cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy followed 4 to 8 weeks later by tositumomab/iodine I 131 tositumomab (anti-CD20 antibody) in 90 eligible patients with previously untreated, advanced stage follicular lymphoma. Treatment was well tolerated. Reversible myelosuppression was the main adverse event and was more severe during CHOP chemotherapy than following radioimmunotherapy. The overall response rate to the entire treatment regimen was 90%, including 67% complete remissions (CRs plus unconfirmed CRs [CRu's]) and 23% partial remissions (PRs). Twenty-seven (57%) of the 47 fully evaluable patients who achieved less than a CR with CHOP improved their remission status after tositumomab/iodine I 131 tositumomab. With a median follow-up of 2.3 years, the 2-year progression-free survival (PFS) was estimated to be 81%, with a 2-year overall survival of 97%. This study has established the feasibility, tolerability, and efficacy of this regimen for patients with advanced follicular lymphoma. This novel treatment appears promising compared with the SWOG's historical experience using CHOP alone and is currently being compared with CHOP plus rituximab in a randomized phase 3 trial (S0016).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kaminski, M. S., Estes, J., Zasadny, K. R., Francis, I. R., Ross, C. W., Tuck, M., Regan, D., Fisher, S., Gutierrez, J., Kroll, S., et al. (2000) · Blood · doi:10.1182/blood.v96.4.1259 · Cited by 525
Cited by
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma
Kaminski, M. S., Tuck, M., Estes, J., Kolstad, A., Ross, C. W., Zasadny, K., Regan, D., Kison, P., Fisher, S., Kroll, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041511 · Cited by 716
Antibody-targeted radiation cancer therapy
Milenic, D. E., Brady, E. D., & Brechbiel, M. W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1413 · Cited by 380
New Treatment Options Have Changed the Survival of Patients With Follicular Lymphoma
Fisher, R. I., LeBlanc, M., Press, O. W., Maloney, D. G., Unger, J. M., & Miller, T. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.1674 · Cited by 375
Self-citationAntibody Pretargeting Advances Cancer Radioimmunodetection and Radioimmunotherapy
Goldenberg, D. M., Sharkey, R. M., Paganelli, G., Barbet, J., & Chatal, J.-F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8471 · Cited by 351
Metadata
- Authors
- Press, O. W., Unger, J. M., Braziel, R. M., Maloney, D. G., Miller, T. P., LeBlanc, M., Gaynor, E. R., Rivkin, S. E., & Fisher, R. I.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2003-09-01
- Volume
- 102
- Issue
- 5
- Pages
- 1606-1612
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1563765846
- Cited by
- 174
- References
- 1
- FWCI
- 15.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. https://app.cochat.ai/papers/10.1182/blood-2003-01-0287
- The paper
- Press, O. W., Unger, J. M., Braziel, R. M., Maloney, D. G., Miller, T. P., LeBlanc, M., Gaynor, E. R., Rivkin, S. E., & Fisher, R. I. (2003). A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood. https://doi.org/10.1182/blood-2003-01-0287
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.